Wedbush Downgrades Sangamo BioSciences (SGMO) to Neutral

November 1, 2016 6:16 AM EDT
Get Alerts SGMO Hot Sheet
Price: $3.65 -7.59%

Rating Summary:
    8 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade SGMO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush downgraded Sangamo BioSciences (NASDAQ: SGMO) from Outperform to Neutral with a price target of $4.00.

Analyst Liana Moussatos commented, "While we believe Sangamo's new management has positively reorganized the company for the longer term with clear goals and reliable success, the pipeline overhaul has created a gap and lack of material clinical catalysts for the Street until 2018. Consequently, we are downgrading to Neutral and view SGMO as appropriate for investors with a longer-term horizon."

For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.

Shares of Sangamo BioSciences closed at $3.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

Liana Moussatos

Add Your Comment